Oct 30, 2014 7:00am EDT NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
Oct 23, 2014 7:00am EDT NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
Oct 16, 2014 7:00am EDT NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
